A recent study indicates that individuals who discontinue new weight-loss injections like semaglutide or tirzepatide can put back on lost weight at a significantly accelerated pace than those who halt traditional diet and exercise programs.
Research printed in a prominent medical journal demonstrates that while obese individuals often shed substantial amounts of their body weight while undergoing treatment, the mass comes back at an average rate of 0.8 kg per month after stopping.
"Individuals purchasing such medications should be informed of the risk of quick weight regain when the treatment ends," stated expert Dr. Susan Jebb.
Such speed of recovery means a return to starting weight within about 18 months.
Analyzing Approaches
The study, which reviewed dozens of studies involving over 9,000 of patients, contrasted the outcomes of these new drugs with other pills.
Researchers emphasize that people who shed pounds through dieting generally have a slower weight regain—perhaps 100 grams monthly—once they finish.
Understanding the Rapid Regain
Nutrition scientists propose the mode of action of the injections accounts for the amplified weight return.
These medications imitate a body's own chemical called GLP-1, which helps regulate hunger.
"Long-term administration of GLP-1 concentrations far above than normal might result in the system to produce less of its endogenous GLP-1, and may also reduce sensitivity to its effects," noted Dr. Adam Collins, a nutrition expert.
"Discontinuation of this medication means appetite is uncontrolled, making excessive eating far more likely."
An Ongoing Condition?
Health authorities advise the injections for people with weight-linked medical conditions, accompanied by prescribed lifestyle changes.
A number of clinicians contend that, considering the significant potential of relapse, the therapy should be considered ongoing.
This view is supported by pharmaceutical companies, who note that the results "highlight the persistent nature of excess weight," comparing it to managing diseases like hypertension.
Patient Experiences
People who have come off the medication explain a powerful resurgence of hunger.
"I experienced a switch flipping and you're instantly starving," said one woman.
This challenge is compounded if individuals have not developed lasting lifestyle or habit modifications during treatment.
Growing Use
Survey data show that millions of people in the UK have tried these injections in the past year, with interest being substantial.
- Use is greater among women than males.
- The 40s and 50s demographic shows the greatest usage rates.
- A large proportion access the medications through private prescriptions rather than the NHS.
In conclusion, clinicians stress that while GLP-1 drugs are potent agents for shedding pounds, they are not a permanent cure and lasting health benefits hinges on ongoing lifestyle support.
